BTIG Research Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $25.00

Health Catalyst (NASDAQ:HCATGet Rating) had its target price reduced by BTIG Research from $35.00 to $25.00 in a report issued on Wednesday morning, The Fly reports.

Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada decreased their price objective on Health Catalyst from $35.00 to $19.00 in a report on Wednesday, May 11th. Canaccord Genuity Group decreased their price objective on Health Catalyst from $35.00 to $17.00 in a report on Wednesday, May 11th. Guggenheim began coverage on Health Catalyst in a report on Wednesday, April 13th. They issued a buy rating and a $39.00 price objective for the company. Citigroup reduced their price target on Health Catalyst from $45.00 to $25.00 in a report on Wednesday, May 11th. Finally, Piper Sandler reduced their price target on Health Catalyst from $38.00 to $21.00 in a report on Wednesday, May 11th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Buy and an average price target of $33.17.

Health Catalyst Price Performance

HCAT opened at $16.74 on Wednesday. The business’s 50-day moving average price is $15.03 and its two-hundred day moving average price is $21.01. Health Catalyst has a 1 year low of $11.25 and a 1 year high of $59.50. The company has a market capitalization of $907.06 million, a price-to-earnings ratio of -5.40 and a beta of 1.07.

Health Catalyst (NASDAQ:HCATGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.03. The company had revenue of $68.09 million during the quarter, compared to analysts’ expectations of $66.01 million. Health Catalyst had a negative return on equity of 19.88% and a negative net margin of 57.95%. Health Catalyst’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.37) EPS. Sell-side analysts anticipate that Health Catalyst will post -1.83 earnings per share for the current fiscal year.

Insider Transactions at Health Catalyst

In other news, insider Linda Llewelyn sold 1,860 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares in the company, valued at $954,945.51. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Linda Llewelyn sold 1,860 shares of Health Catalyst stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the completion of the sale, the insider now directly owns 60,173 shares in the company, valued at $954,945.51. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Daniel H. Orenstein sold 2,838 shares of Health Catalyst stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $14.85, for a total transaction of $42,144.30. Following the completion of the sale, the general counsel now owns 103,671 shares of the company’s stock, valued at $1,539,514.35. The disclosure for this sale can be found here. Insiders sold a total of 6,255 shares of company stock worth $93,877 over the last quarter. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently made changes to their positions in the business. UMB Bank N A MO acquired a new stake in shares of Health Catalyst in the fourth quarter valued at approximately $30,000. Fairfield Bush & CO. acquired a new stake in shares of Health Catalyst in the first quarter valued at approximately $25,000. Manchester Capital Management LLC raised its position in shares of Health Catalyst by 667.5% in the first quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock valued at $30,000 after buying an additional 1,008 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in Health Catalyst during the first quarter valued at approximately $33,000. Finally, Sageworth Trust Co of South Dakota acquired a new position in Health Catalyst during the fourth quarter valued at approximately $61,000. 97.53% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Recommended Stories

The Fly logo

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.